- LegitScript Certified
- US-licensed pharmacy
- Ships in 3 to 5 days
- Concentration
- PT-141 (Bremelanotide)
- Purity
- Provider reviewed
- Unit
- Monthly supply
- Category
- Sexual Health
Common questions
Is this the FDA-approved Vyleesi product?
Is bremelanotide approved for men?
How does it differ from sildenafil?
PT-141 (Bremelanotide)
Bremelanotide, a different mechanism from ED medicines.
Compounded bremelanotide, also called PT-141, reviewed by a licensed provider. Vyleesi is the FDA-approved bremelanotide product for a specific form of low sexual desire in premenopausal women; this listing is for a compounded preparation.
- Acts on desire, not blood flow
- Use about 45 minutes before
- Subcutaneous injection
- Provider reviewed, real pricing up front
What's Included
- ✓Medication and supplies
- ✓Provider visit and unlimited follow-ups
- ✓Free expedited shipping
- ✓Injection home kit included
Pause, change, or cancel anytime from your account.
This medication is prepared by a licensed compounding pharmacy. Compounded medications are not reviewed by the FDA for safety or effectiveness and are dispensed only after a licensed provider determines they are appropriate for you.
How Would You Like To Pay?
Choose Your Plan
1-Month Plan
$170- $170 Billed Today
- Then $170 Every Month
- Cancel Anytime
Or pay with
$170 billed today, then every month until canceled.
By completing your order, you agree to the HealthRX.com Terms & Conditions and Privacy Policy, and confirm you are 18 or older.
Your provider confirms the strength and dose after intake. Payment does not guarantee a prescription.
After checkout you complete a short medical review in your member portal, and a US-licensed provider reviews it before your PT-141 ships.
A straightforward path to care
Select your plan
Choose your treatment options and complete secure checkout. Then complete the online health intake.
Provider review
A licensed physician (MD) reviews your completed intake and decides whether bremelanotide is right for you.
Ships to your door
If approved, a US-licensed pharmacy prepares your injection and ships it discreetly in 3 to 5 days.
Ongoing support
Message your care team any time. Your provider can adjust timing or dose based on how you respond and tolerate it.
Works on desire, not blood flow
Bremelanotide acts on melanocortin receptors in the brain that are involved in sexual desire, a different pathway from blood-flow medications.
Vyleesi and this formulation
Vyleesi is FDA approved for premenopausal women with acquired, generalized HSDD. This listing is for compounded bremelanotide, a different preparation without that product approval.
Use it around 45 minutes before
You give a small subcutaneous injection about 45 minutes before intimacy, not on a daily schedule.
Review other medications
Your provider reviews other medicines and medical conditions before deciding whether a prescription is appropriate.
About PT-141 (Bremelanotide)
Bremelanotide activates melanocortin receptors. Its mechanism differs from PDE5 medicines such as sildenafil, which act on blood flow. A different mechanism does not establish that combining treatments is beneficial or appropriate for a particular person.
- Licensed provider evaluation
- Melanocortin-receptor mechanism
- Compounded preparation with product-specific instructions
- Pricing shown before checkout
You inject a small dose
A subcutaneous injection is given about 45 minutes before intimacy.
It activates melanocortin receptors
Bremelanotide stimulates melanocortin receptors in the hypothalamus, part of the brain's desire circuitry.
Desire signaling is engaged
This pathway is separate from the blood-flow mechanism that PDE5 medicines use.
Bremelanotide engages the brain pathways tied to sexual desire. It does not act on blood flow, so it works differently from ED pills.
What the research shows
Bremelanotide is the active ingredient in Vyleesi, which the FDA approved in 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder. Its evidence base comes from the two randomized, placebo-controlled RECONNECT phase 3 trials. The trials studied the approved product and population, not this compounded formulation.
+0.35
Across the two RECONNECT phase 3 trials, bremelanotide increased the FSFI sexual-desire score versus placebo in premenopausal women with HSDD, an integrated change of 0.35 points (P<.001).
Kingsberg et al., Obstet Gynecol 2019
Less distress
In the same trials, bremelanotide reduced desire-related distress on the FSDS-DAO versus placebo, an integrated change of 0.33 points (P<.001).
Kingsberg et al., Obstet Gynecol 2019
52 weeks
In a 52-week open-label extension, no new safety signals were seen. The most common side effect was nausea, reported by about 40 percent of participants.
Simon et al., Obstet Gynecol 2019
PT-141 (bremelanotide) or PDE5 pills like sildenafil
Two different mechanisms
| PT-141 (bremelanotide) | PDE5 pills like sildenafil | |
|---|---|---|
| How it works | Acts on desire pathways in the brain | Increases blood flow in the body |
| What it targets | Low desire and arousal | Physical erection and blood flow |
| Format | Subcutaneous injection | Oral tablet |
| When you use it | About 45 minutes before | About 30 to 60 minutes before |
| Regulatory status | This preparation is compounded; Vyleesi has a separate product approval | FDA-approved for erectile dysfunction |
| Combination evidence | A different mechanism does not establish combination benefit | Requires evaluation of the specific medicines and patient |
What to expect
Your provider reviews your symptoms, medications, blood pressure, and medical history before deciding whether to prescribe. The RECONNECT studies evaluated a defined bremelanotide product in premenopausal women with acquired, generalized hypoactive sexual desire disorder. Those findings do not establish equivalent outcomes for this compounded preparation or for other populations.
About 45 minutes before
You inject
Give a small subcutaneous injection roughly 45 minutes before intimacy.
45 to 90 minutes
It takes effect
Effects on desire typically begin within this window after the injection.
Up to a few hours
Your window
Effects can last for a few hours. Do not use more than one dose in 24 hours.
After a few tries
Dial in with your provider
Your provider adjusts timing or dose based on how you respond and how well you tolerate it.
Safety and side effects
The approved Vyleesi label identifies nausea, flushing, headache, injection-site reactions, increased blood pressure, and focal hyperpigmentation among relevant risks. Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. The provider must evaluate the risks of the prescribed formulation and give its specific instructions.
Common
- Nausea, especially early on
- Flushing
- Headache
- Reaction at the injection site
Less common
- Temporary rise in blood pressure
- Vomiting
- Fatigue
Seek care
- Darkening of the skin or gums with repeated use
- Significant or lasting blood pressure increase
Not for use during pregnancy or when trying to conceive. Not for people with uncontrolled high blood pressure or known cardiovascular disease. Do not use more than one dose in 24 hours or more than eight per month. Tell your provider about all heart and blood pressure conditions. This compounded use is off-label except in premenopausal women with HSDD.
Frequently asked questions
Does bremelanotide cause nausea?
Other sexual health options
Approval is never automatic.
An independent US-licensed clinician reviews every request. If they decide the treatment is not right for you, you get a full refund for the medication.
Prescriptions are filled by a US-licensed pharmacy and shipped free, in discreet packaging, on every plan.
LegitScript-certified · Cert 50087439
Compounded medications are prepared by a US-licensed pharmacy and are not reviewed by the FDA for safety or effectiveness. Products are dispensed only after a licensed provider determines they are appropriate. Information here is educational and is not a substitute for medical advice.